Conclusion
INFLUENZA, COMPLICATIONS, EMA
In conclusion, this study demonstrated that QIV can be reproducibly manufactured to yield a well-tolerated, safe, and immunogenic vaccine in people aged 9–40 years and that it met all EMA immunogenicity criteria in adults. In adults, inactivated QIV induced comparable immune responses to TIV for A strains and the B lineage common to both QIV and TIV.These data support the use of Bio Farma QIV for seasonal vaccination in children and adult subjects, which may enhance the protection against influenza and decrease the burden associated with influenza complications. The immunogenicity of the three batches of QIV was equivalent for all four strains.